Exploring the link between fatty liver disease and coronary artery disease severity
Positive Association Between Ultrasonographic Fatty Liver Indicator and the Severity of Coronary Artery Disease
Chongqing Medical University · NCT06541132
This study is trying to see if a special ultrasound test for fatty liver can help understand how severe coronary artery disease is in people with fatty liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 190 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Chongqing Medical University (other) |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT06541132 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between the Ultrasonographic Fatty Liver Indicator (US-FLI) and the severity of coronary artery disease (CAD) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). A total of 204 patients who underwent invasive coronary angiography at the Second Affiliated Hospital of Chongqing Medical University will be evaluated. The study will collect clinical information and abdominal ultrasound images to assess hepatic steatosis using US-FLI, and the severity of CAD will be measured using the SYNTAX score. Multivariate logistic regression will analyze the association between US-FLI and SYNTAX scores, while receiver operating characteristic curves will determine the predictive accuracy of US-FLI.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have undergone coronary angiography due to symptoms like chest pain or tightness.
Not a fit: Patients with incomplete clinical data, previous coronary stent implantation, or other specified exclusion criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the use of US-FLI as a predictive tool for assessing CAD severity in patients with fatty liver disease.
How similar studies have performed: While the relationship between fatty liver disease and coronary artery disease has been explored, this specific approach using US-FLI in conjunction with SYNTAX scores is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients older than 18 years old * Patients underwent ICA due to chest pain, chest tightness or other reasons in our hospital from August 2022 to December 2023 were included in our study Exclusion Criteria: * Incomplete clinical data * previous coronary stent implantation * no abdominal ultrasound examination * poor ultrasound image quality * congenital heart disease * tumor * thyroid diseases and infectious diseases
Where this trial is running
Chongqing, Chongqing Municipality
- The Second Affiliated Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Tingqiu Wang
- Email: w857683014@163.com
- Phone: +8617815370539
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease, SYNTAX Score, Ultrasonography, Coronary Artery Disease, SYNTAX score